Scarica l'app Stockscreener
2.89
0.35%
0.01
Precedente Chiudi:
$2.88
Aprire:
$2.91
Volume 24 ore:
15,116
Relative Volume:
0.77
Capitalizzazione di mercato:
$25.58M
Reddito:
-
Utile/perdita netta:
$-30.16M
Rapporto P/E:
-8.50
EPS:
-0.34
Flusso di cassa netto:
$-39.49M
1 W Prestazione:
-0.69%
1M Prestazione:
-0.69%
6M Prestazione:
-9.97%
1 anno Prestazione:
+564.67%
Intervallo 1D:
$2.8824
$2.92
Intervallo di 1 settimana:
$2.88
$2.9406
Portata 52W:
$0.326
$4.60
Dare Bioscience Inc Stock (DARE) Company Profile
Nome
Dare Bioscience Inc
Settore
Industria
Telefono
858-926-7655
Indirizzo
3655 NOBEL DRIVE, SAN DIEGO, CA
Confronta DARE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
2.89 | 25.75M | 0 | -30.16M | -39.49M | -0.34 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Dare Bioscience Inc Borsa (DARE) Ultime notizie
Q2 EPS Estimate for Daré Bioscience Increased by Analyst - Defense World
Daré outlines expanded dual path strategy targeting $4.5B hormone therapy market while accelerating commercialization in Q4 2025 - MSN
Daré Bioscience’s Earnings Call: Strategic Moves Amid Challenges - TipRanks
Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2025 Earnings Call Transcript - Insider Monkey
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates - MSN
Dare Bioscience Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Dare Bioscience (DARE) Expands Strategy to Enhance Value for Sta - GuruFocus
Dare Bioscience Inc (DARE) Q1 2025 Earnings Call Highlights: Strategic Expansions and Cost ... - Yahoo Finance
Daré Bioscience Expands Women’s Health Portfolio - TipRanks
Earnings call transcript: Dare Bioscience Q1 2025 unveils new products and cost cuts By Investing.com - Investing.com South Africa
Earnings call transcript: Dare Bioscience Q1 2025 unveils new products and cost cuts - Investing.com India
Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update - The Manila Times
Daré Bioscience Q1 2025 Financial Results and Company Update - TradingView
Daré Bioscience Unveils Major Commercial Push: 4 Women's Health Products Coming to $4.5B Market by 2026 - Stock Titan
Daré Bioscience (DARE) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Daré Bioscience, Inc. (NASDAQ:DARE) Shares Purchased by Renaissance Technologies LLC - Defense World
Daré Bioscience to Host First Quarter 2025 Financial - GlobeNewswire
Daré Bioscience Q1 Earnings: Women's Health Innovator to Share Latest Financial Results May 13 - Stock Titan
Geode Capital Management LLC Purchases 3,593 Shares of Daré Bioscience, Inc. (NASDAQ:DARE) - Defense World
Daré Bioscience targets Q4 2025 for Sildenafil Cream launch via 503B compounding - MSN
Daré Bioscience to Present at the Fierce Pharma Engage - GlobeNewswire
Daré CEO Unveils Game-Changing Women's Health Pipeline: Sildenafil Cream Launch Timeline Confirmed - Stock Titan
Daré Bioscience (NASDAQ:DARE) Share Price Crosses Below 200-Day Moving Average – Here’s What Happened - Defense World
Dare Bioscience granted extension by Nasdaq to regain compliance - Investing.com Australia
Daré Bioscience to Present at the Jones Healthcare and - GlobeNewswire
Daré's Game-Changing Strategy: Sildenafil Cream Heads to Prescription Market Earlier Than Expected - Stock Titan
Daré Bioscience Q1 EPS Estimate Increased by HC Wainwright - Defense World
Q1 EPS Estimate for Daré Bioscience Decreased by Analyst - Defense World
HC Wainwright Forecasts Daré Bioscience FY2029 Earnings - Defense World
Short Interest in Daré Bioscience, Inc. (NASDAQ:DARE) Rises By 22.2% - Defense World
Daré Bioscience (NASDAQ:DARE) Receives Buy Rating from HC Wainwright - Defense World
Daré Bioscience Earnings Call: Strategic Progress Amid Challenges - TipRanks
Daré Bioscience (DARE) Anticipates Revenue Boost from Sildenafil Cream in 2025 - GuruFocus
Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2024 Earnings Call Transcript - Insider Monkey
Dare Bioscience Inc (DARE) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ... - Yahoo Home
Earnings call transcript: Dare Bioscience Q4 2024 focuses on women’s health innovations - Investing.com
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Dare Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Daré Bioscience Reports Full Year 2024 Financial Results - MarketScreener
DARE BIOSCIENCE Earnings Results: $DARE Reports Quarterly Earnings - Nasdaq
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update - TradingView
Daré Bioscience Reveals New Revenue Strategy: Sildenafil Cream Launch Coming Q4 2025 - Stock Titan
Daré Bioscience (NASDAQ:DARE) Stock Price Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Upcoming: Daré Bioscience Full Year Results Reveal Women's Health Innovation Progress - StockTitan
Daré Bioscience to Host Full Year 2024 Financial Results - GlobeNewswire
Daré Bioscience (DARE) Projected to Post Quarterly Earnings on Thursday - Defense World
Daré Bioscience (NASDAQ:DARE) Shares Cross Below 200-Day Moving Average – Should You Sell? - Defense World
Dare Bioscience, Inc. to Host Earnings Call - ACCESS Newswire
Daré Bioscience and Theramex Announce Co-Development and - GlobeNewswire
Dare Bioscience and Theramex Announce Co-Development and Licensing Agreement for A Potential Biodegradable Long-Acting Contraceptive Implant - Marketscreener.com
Daré, Theramex partner on biodegradable contraceptive implant - Investing.com
Dare Bioscience Inc Azioni (DARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):